Revotek Receives Clearance from the National Health Commission of China for the World First Clinical Trial for 3D Bioprinted Stem Cell Vascular Grafts
CHENGDU, China, Feb. 21, 2022 /PRNewswire/ -- Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS. "The clearance marks an important milestone for Revotek. We are excited to advance REVOVAS,...
Fiducia’s Inaugural Fund Launched With Initial Size of 3.3 Billion Yen; Fundraising to Continue
TOKYO, Feb. 21, 2022 /PRNewswire/ -- Fiducia Inc. announced that it has executed the first closing of its inaugural fund (Fiducia Growth Tech Limited Liability Investment Limited Partnership), with an initial size of 3.26 billion yen. The fund, which has started investments, will continue its fund-raising activity to grow in scale over the period of about one year....
Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development
Recorded operating profit KRW 88.9 billion and net profit KRW 31.6 billion in 2021 with the outcome of its relentless focus on R&D Attributed to export upswing of Nabota, KRW 1.1 trillion overseas technology transfer of Fexuclue tablets, and growth of highly profitable ETC drugs SEOUL, South Korea, Feb....
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer
SEOUL, South Korea, Feb. 21, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today the appointment of Almira Chabi, M.D. as Chief Medical Officer and Chief Development Officer at HanAll Pharmaceutical International (HPI), a U.S. entity wholly owned by HanAll Biopharma, to strengthen its R&D capability. "We are extremely pleased to welcome Dr....
Free online course from the Johns Hopkins Bloomberg School of Public Health can help amplify efforts to reduce tobacco use
BALTIMORE, Feb. 21, 2022 /PRNewswire/ -- Join the thousands of tobacco control professionals from across the globe who have expanded their knowledge on key issues by taking the free online course Global Tobacco Control: Learning from the Experts from the Institute for Global Tobacco Control at the Johns Hopkins Bloomberg School of Public Health. Join the thousands...
Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2）in Frontiers in Immunology
NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 21, 2022 /PRNewswire/ -- recently -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced the publication of preclinical research of AN3025 (anti-hTNFR2）in the peer-reviewed journal Frontiers in Immunology. The article entitled "Antagonistic Antibody Targeting...
Harbour BioMed Announces IND Approval for Next-Gen Anti-TSLP Fully Human Monoclonal Antibody
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 21, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that China National Medical Products Administration (NMPA) had approved its investigational new drug (IND) application for HBM9378 (or SKB378 as referred to by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech"), a subsidiary of Sichuan...
Hong Kong Life gives away 100 “We-Care Backpack” comprising mandatory quarantine subsidy, free hospital income benefit and multiple offers
HONG KONG, Feb. 21, 2022 /PRNewswire/ -- The COVID-19 epidemic situation remains volatile recently and everyone may be subject to mandatory quarantine at any time. General public inevitably feel worried about personal health and life changes. Hong Kong Life would provide the general public with positive energy and support by offering 100 "We-Care Backpack" comprising Mandatory Quarantine Subsidy, Free...
Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer
NEWARK, Del. and NANJING, China, Feb. 21, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Joel Edwards as chief business officer. In this position, he is responsible for strategic leadership over all aspects of the company's global business development and alliance management activities. He will report to Dr. Mingjiu...
CanSinoBIO’s Convidecia™ Approved as Heterologous Booster in China
TIANJIN, China, Feb. 21, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™) has been approved by the Joint Prevention and Control Mechanism of the State Council of China ("State Council") as a heterologous booster, making it the first adenovirus-vectored vaccine to...
